Login to Your Account

ADA Roundup

Tuesday, June 12, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, reported results from a post-hoc analysis testing DPP-4 inhibitor Tradjenta (linagliptin) on albuminuria in patients with Type II diabetes who had early diabetic nephropathy, with data showing a 29 percent reduction in a urinary albumin-to-creatinine ratio with linagliptin plus angiotensin-converting enzyme inhibitors (ACEs) and angiotensin receptor blockers (ARBs) vs. ACEs/ARBs alone at 24 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription